Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
18 juin 2024 16h30 HE | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE | Tenaya Therapeutics, Inc.
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
02 mai 2024 17h00 HE | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h30 HE | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
21 sept. 2023 16h05 HE | Tenaya Therapeutics, Inc.
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
16 août 2023 08h00 HE | Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...
22157.jpg
Worldwide Precision Cardiology Industry to 2027 - by Offering, Sample Type, Technology, Application, End-user and Region
26 oct. 2022 07h48 HE | Research and Markets
Dublin, Oct. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Precision Cardiology Market: Competition Forecast and Opportunities to 2027" report has been added to ResearchAndMarkets.com's offering.The...
Global Precision Cardiology Market
Global Precision Cardiology Industry 2021-2031: Focus on Offering, Sample, Technology, Application, End-user, and Region
28 févr. 2022 06h28 HE | Research and Markets
Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and...
Healthtech Solutions, Inc. (HLTT), Parent Company of Cutting-Edge Medical Technology Companies, Files Reg A With SEC
17 mars 2021 08h30 HE | Healthtech Solutions, Inc.
March 8, 2021, filing to raise up to $75 million.  Maximum of 1,500,000 shares of Series B preferred stock offered at price of $50 per share.Healthtech Solutions, Inc. is organized to pursue...
Reports and Data.jpeg-01
Cardiomyopathy Medication Market To Reach USD 1,148.9 Million By 2026 | Reports And Data
04 nov. 2019 12h11 HE | Reports and Data
New York, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Rising prevalence of cardiomyopathy diseases, new product development for targeted cardiac illnesses, collaborations for medical advancements and...